Sign in
Taking people in South KoreaNo phase

Comparing newer and standard immunochemotherapy for relapsed high-grade B-cell lymphoma

Compares newer and standard immune treatments in adults with returned aggressive B-cell lymphoma.

Key facts

Who runs it
Sung-Soo Park
Where
Seoul, South KoreaSee the 2 sites
Trial code
Registry title
Immunotherapy in Lymphoma
Status
Recruiting
People taking part
72 people, planned
Started
26 Jun 2024
Planned end
31 Dec 2025
Type of study
Observational, 2 groups
Treatments tested
  • CAR-T Therapy
  • Bispecific antibody
  • Antibody-Drug Conjugate
  • Monoclonal antibody
  • Proteasome Inhibitor
  • IMiD treatment
Record updated
28 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with relapsed or refractory aggressive B-cell lymphoma who have already had immunochemotherapy. It compares newer and classical immunochemotherapy.

Age
19 to 74 years
Sex
All sexes can join.
Disease stage
Relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma, diagnosed after January 2015.
Earlier treatment
Must have received immunochemotherapy for relapsed or refractory lymphoma.

Main reasons for not taking part

  • Lymphoma that has progressed to acute leukemia
  • A solid tumor that developed during treatment
  • Active infection, such as acute pneumonia, viral infection, active hepatitis B or active pulmonary tuberculosis

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adults aged 19 to 74 years
  • Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
  • Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma

Who cannot take part

  • Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
  • Patients who have progressed to acute leukemia
  • Patients who developed solid tumor during treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 74 years old?

Where in South Korea

  • Seoul St. Mary HospitalSeoul, South KoreaContact: Sung-Soo Park, MD. PhD.Taking people
  • Yeoido St. Mary HospitalSeoul, South KoreaContact: Young-Woo Jeon, MD. PhD.Taking people

About the trial

What the trial wants to find out

The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:

Read full original descriptionShow less

Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?

Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.

Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.

The 2 groups in the trial

  • Advanced immunochemotherapy

    Relapsed/refractory high grade B cell lymphoma patients treated with either chimeric antigen receptor T cell therapy, bispecific antibody, or antibody-drug conjugate

    Treatment: CAR-T Therapy, Bispecific antibody, and Antibody-Drug Conjugate

  • Classical Immunochemotherapy

    Relapsed/refractory high grade B cell lymphoma patients treated with either proteasome inhibitor, immune modulatory drug, or monoclonal antibody.

    Treatment: Monoclonal antibody, Proteasome Inhibitor, and IMiD treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
Plain-language title
Comparing newer and standard immunochemotherapy for relapsed high-grade B-cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06796517, who can take part
Record updated
28 January 2025